TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05108961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: one session with precise acupunture points

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm
Study: NCT05295940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT04605185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: 100mg Qd/150mg Qd/100mg Bid, po

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: 240 mg, iv drip,q3w
Study: NCT06619769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigator support for eSense-Cancer
Description: The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigator support for eSense-Cancer
Description: The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
Study: NCT06627491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagined muscle contractions
Description: The intervention involved imagining, with no physical movement, of muscle contractions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagined muscle contractions
Description: The intervention involved imagining, with no physical movement, of muscle contractions.
Study: NCT06632561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills one tablet daily for 6 months
Study: NCT06273839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)
Study: NCT05275803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: The participant does not use probiotics after non-surgical periodontal treatment.
Study: NCT05982717

Intervention type: OTHER
Intervention: No intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT04620421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm-based Multitask Training
Description: Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
Study: NCT05271994

Intervention type: PROCEDURE
Intervention: endoscopic biliary drainage
Description: endoscopic biliary drainage
Study: NCT06509412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LANAP surgical protocol using ND:YAG 1064 laser
Description: A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LANAP surgical protocol using diode 940 laser
Description: Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
Study: NCT06639074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Description: Given ID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed
Description: Given IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed
Description: Given IM
Study: NCT04843072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolut R/PRO bioprosthesis
Description: To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien S3/Ultra bioprosthesis
Description: Edwards Sapien S3/Ultra bioprosthesis
Study: NCT06213935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: 10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
Study: NCT05682898

Intervention type: PROCEDURE
Intervention: Timing of colorectal cancer surgery
Description: The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.

Intervention type: PROCEDURE
Intervention: Timing of colorectal cancer surgery
Description: The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
Study: NCT04545411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: 4-Week, double-blind, once daily oral 10mg dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: 4-Week, double-blind, once daily oral 10mg dapagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMD-477
Description: 4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
Study: NCT06507098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted training
Description: Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nurse training
Description: A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
Study: NCT06225804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK112
Description: In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
Study: NCT05402904

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: nerve conduction study
Description: Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: nerve conduction study
Description: Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
Study: NCT05892536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental regenerative endodontics
Description: regenerative procedures performed in necrotic mature permanent teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental regenerative endodontics
Description: regenerative procedures performed in necrotic mature permanent teeth
Study: NCT06166290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 LASER Vaporisation
Description: The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrosurgical Fulguration
Description: The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
Study: NCT05137210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male Counseling and Facility Navigation
Description: At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based ART Initiation and Facility Navigation
Description: At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Intervention
Description: Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm.
Study: NCT05928624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Home Blood Pressure Device and Scale
Description: The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT05580185

Intervention type: DEVICE
Intervention: RESPINOR DXT
Description: Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.

Intervention type: DEVICE
Intervention: RESPINOR DXT
Description: Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
Study: NCT05303337

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool samples will be collected from participants at baseline and W52